



Proactive Health INTEGRATED PRS™ TYPE 2 DIABETES

A Personalized Risk Score for Type 2 Diabetes

MyOme's Integrated Polygenic Risk Score™ (iPRS™) Type 2 Diabetes (T2D) test combines whole-genome insights with clinical risk assessment, delivering a more accurate risk prediction to better guide healthcare decisions and outcomes.



Personalized Risk Prediction Can Enable Tailored Care to Improve Health Outcomes

Hidden Risk Detection

Up to



of T2D risk is due to heritable factors, many of which can be detected as genetic markers by the iPRS test¹

Reliable Risk Stratification

A high iPRS test score predicted a



increase in the 10-year incidence of T2D compared to the low iPRS group*²

From Risk to Prevention

In people at increased risk for T2D,




reduced their incidence of T2D by adopting lifestyle interventions³

The iPRS T2D Test Provides a 10-year Integrated Risk of Developing T2D

Patients can receive an iPRS result if they:

- Are aged 35–70 years old
- Do not have a personal history of T2D
- Do not use insulin or oral antidiabetic medication



*For individuals with high clinical risk



Proactive Health INTEGRATED PRS™ TYPE 2 DIABETES

The Power of Comprehensive Insights

The iPRS T2D test produces a complete risk score and classifies patients as either “increased risk” or “not at increased risk”. Test results can guide healthcare decisions for all patients, especially those at increased risk, by helping to:

Enable Early Detection — Personalize Preventative Care — Optimize Health Outcomes

Key Features



Genome First

The iPRS T2D test is run on a genome sequencing backbone, which allows for broad detection of clinically relevant variants. These variants were identified from genome-wide studies that included more than 180,000 people with T2D.²



Multi-Ancestry Applicability

The iPRS T2D test was validated in >120K patients across ancestrally diverse cohorts, enabling more reliable cross-ancestry risk prediction.



Actionable Reports

Reports provide actionable recommendations for lowering T2D risk based on clinical guidelines^{3,4}, with the option to consult a trained genetic counselor for personalized interpretation and support.

Get Started with Our Simple, Seamless Process

Order	Sample Collection	Sample Analysis	Receive Results
Submit an order via MyOme’s secure portal	Use instructions provided in blood, saliva, or buccal swab collection kits	Return sample to MyOme for sequencing and data analysis	Reports are delivered through MyOme’s secure portal



Interested in personalized T2D risk prediction?
Contact support@myome.com or visit our website to order now.

¹ Bonnefond A, Florez J, et al. Dissection of type 2 diabetes: a genetic perspective. *Lancet Diabetes endocrinol.* (2025). doi:10.1016/S2213-8587(24)00339-5. ² Ratman, D. et al (2024, June). Utility of Polygenic Risk Scores for Prediction of Incident Type 2 Diabetes. poster presented at: The European Human Genetics Conference, Berlin, Germany. ³ Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *JAMA.* (2002). doi: 10.1056/NEJMoa012512. ⁴ American Diabetes Association Professional Practice Committee. Prevention of Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes- 2025.

This test was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.